

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
31 March 2022 (31.03.2022)



(10) International Publication Number
WO 2022/067348 A1

(51) International Patent Classification:

C07K 16/28 (2006.01) A61P 35/00 (2006.01)
A61K 47/68 (2017.01) A61K 39/395 (2006.01)

(21) International Application Number:

PCT/US2021/071609

(22) International Filing Date:

27 September 2021 (27.09.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/084,444 28 September 2020 (28.09.2020) US
63/243,025 10 September 2021 (10.09.2021) US

(71) Applicant: SEAGEN INC. [US/US]; 21823 30th Drive
S.E., Bothell, Washington 98021 (US).

(72) Inventors: ONSUM, Matt; c/o Seagen Inc., 21823 30th
Drive S.E., Bothell, Washington 98021 (US). LU, Hailing;
c/o Seagen Inc., 21823 30th Drive S.E., Bothell, Washing-
ton 98021 (US). WANG, Zejing; c/o Seagen Inc., 21823
30th Drive S.E., Bothell, Washington 98021 (US).

(74) Agent: CHAN, Ngam Fung David et al.; Morrison & Fo-
erster LLP, 12531 High Bluff Drive, Suite 100, San Diego,
California 92130 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(54) Title: HUMANIZED ANTI-LIV1 ANTIBODIES FOR THE TREATMENT OF CANCER

(57) Abstract: Methods for using anti-LIV1 antibodies and antibody-drug conjugates, including anti-LIV1 antibody-drug conjugates, to inhibit proliferation of a cell, as well as for the treatment of cancers, such as, e.g., prostate cancer and melanoma, are provided.

WO 2022/067348 A1